NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 20 04:00PM ET
2.25
Dollar change
-0.04
Percentage change
-1.75
%
IndexRUT P/E- EPS (ttm)-6.39 Insider Own33.78% Shs Outstand20.89M Perf Week-13.13%
Market Cap47.00M Forward P/E- EPS next Y-3.69 Insider Trans14.32% Shs Float13.83M Perf Month-10.00%
Enterprise Value57.10M PEG- EPS next Q-2.25 Inst Own58.54% Short Float14.06% Perf Quarter-59.82%
Income-133.56M P/S47.00 EPS this Y7.31% Inst Trans0.63% Short Ratio5.79 Perf Half Y-57.22%
Sales1.00M P/B1.78 EPS next Y39.93% ROA-65.88% Short Interest1.94M Perf YTD-51.82%
Book/sh1.26 P/C0.57 EPS next 5Y12.12% ROE-127.99% 52W Range1.78 - 10.14 Perf Year-69.26%
Cash/sh3.98 P/FCF- EPS past 3/5Y23.61% 8.03% ROIC-118.86% 52W High-77.81% Perf 3Y-75.70%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-48.91% 31.95% Gross Margin-233.90% 52W Low26.40% Perf 5Y-99.05%
Dividend TTM- EV/Sales57.10 EPS Y/Y TTM37.54% Oper. Margin-15364.20% Volatility2.85% 5.42% Perf 10Y-99.46%
Dividend Ex-Date- Quick Ratio3.57 Sales Y/Y TTM-72.22% Profit Margin-13356.00% RSI (14)40.10 Recom1.40
Dividend Gr. 3/5Y- - Current Ratio3.57 EPS Q/Q-49.29% SMA20-7.77% Beta0.70 Target Price22.33
Payout- Debt/Eq3.53 Sales Q/Q- SMA50-17.39% Rel Volume0.52 Prev Close2.29
Employees155 LT Debt/Eq3.25 EarningsMay 14 AMC SMA200-55.01% Avg Volume335.56K Price2.25
IPOJul 31, 2014 Option/ShortYes / Yes EPS/Sales Surpr.-15.98% - Trades Volume173,955 Change-1.75%
Date Action Analyst Rating Change Price Target Change
Jun-25-24Initiated Oppenheimer Outperform $25
Apr-30-24Initiated H.C. Wainwright Buy $30
Jul-07-22Upgrade Truist Hold → Buy $4
Jul-23-21Downgrade Cantor Fitzgerald Overweight → Neutral
May-03-21Downgrade SVB Leerink Outperform → Mkt Perform $5
Apr-29-21Downgrade Truist Buy → Hold $30 → $9
Apr-29-21Downgrade RBC Capital Mkts Outperform → Sector Perform $6
Apr-29-21Downgrade Chardan Capital Markets Buy → Neutral $5
Dec-16-20Initiated UBS Neutral $13
Nov-12-20Upgrade Raymond James Underperform → Mkt Perform
Jun-05-25 04:01PM
May-14-25 04:33PM
04:05PM
May-02-25 04:01PM
Apr-24-25 01:58PM
07:47AM Loading…
Apr-15-25 07:47AM
07:40AM
Apr-04-25 04:05PM
Mar-31-25 04:01PM
Mar-03-25 04:01PM
Feb-28-25 04:00PM
Feb-25-25 07:00AM
Feb-05-25 04:05PM
Dec-06-24 04:05PM
Nov-20-24 04:05PM
07:00AM Loading…
Nov-18-24 07:00AM
Nov-15-24 04:05PM
Nov-04-24 06:00PM
05:06PM
04:39PM
Oct-16-24 08:00AM
Oct-11-24 12:00PM
Sep-05-24 07:30AM
Sep-04-24 04:05PM
Sep-03-24 09:55AM
Aug-12-24 04:35PM
04:05PM
Aug-02-24 07:00AM
Aug-01-24 08:00AM
Jul-18-24 09:40AM
02:45AM Loading…
Jul-17-24 02:45AM
Jul-16-24 09:55AM
Jul-10-24 08:00AM
Jun-18-24 08:00AM
Jun-11-24 08:00AM
08:00AM
May-10-24 03:36PM
09:35AM
May-09-24 11:55PM
05:45PM
04:05PM
May-03-24 08:00AM
May-02-24 10:01AM
Apr-30-24 07:39AM
Apr-29-24 08:33AM
Apr-25-24 04:05PM
Apr-23-24 09:40AM
Apr-19-24 09:35AM
Apr-04-24 09:40AM
08:34AM
Apr-03-24 09:35AM
Mar-27-24 09:35AM
Mar-21-24 07:52AM
Mar-20-24 05:33AM
Mar-19-24 09:40AM
Mar-18-24 10:53PM
04:20PM
04:05PM
Mar-06-24 03:07PM
Feb-28-24 04:05PM
Feb-27-24 06:10AM
Feb-22-24 06:15AM
Feb-12-24 08:00AM
Feb-08-24 07:00AM
Feb-05-24 07:45AM
Feb-01-24 05:30PM
Jan-29-24 08:00AM
Jan-04-24 08:27AM
Dec-07-23 04:05PM
Nov-28-23 04:05PM
Nov-09-23 04:51PM
04:05PM
Nov-06-23 08:00AM
Nov-04-23 05:54PM
Oct-24-23 12:30PM
Sep-26-23 04:05PM
Sep-21-23 04:05PM
Sep-05-23 04:05PM
Aug-21-23 04:05PM
Aug-14-23 08:00AM
Aug-10-23 04:20PM
04:05PM
Jun-12-23 08:00AM
Jun-02-23 08:00AM
May-25-23 06:30AM
May-18-23 09:00AM
09:00AM
May-11-23 04:47PM
04:05PM
May-10-23 04:05PM
May-02-23 04:30PM
Apr-23-23 01:00PM
Apr-21-23 06:03AM
Apr-18-23 08:00AM
Apr-17-23 04:05PM
Apr-04-23 09:40AM
Mar-30-23 04:05PM
Mar-02-23 10:23AM
Feb-27-23 04:05PM
Jan-18-23 04:05PM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soparkar PeterCHIEF OPERATING OFFICERMay 15 '25Sale2.002,9605,92039,154May 16 04:46 PM
Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICERMay 15 '25Sale2.009241,84813,768May 16 04:45 PM
Fischer LaurentCEO, PRESIDENT AND DIRECTORMay 15 '25Sale2.009,12618,25287,488May 16 04:44 PM
Leonard Braden Michael10% OwnerMar 26 '25Buy5.0420,407102,841125,207Apr 28 03:24 PM
Leonard Braden Michael10% OwnerMar 27 '25Buy5.1916,59386,089141,800Apr 28 03:24 PM
Leonard Braden Michael10% OwnerApr 22 '25Buy3.00300,000900,0003,057,526Apr 24 09:35 AM
Leonard Braden Michael10% OwnerApr 23 '25Buy2.9850,000148,950191,800Apr 24 09:35 AM
Leonard Braden Michael10% OwnerMar 31 '25Buy4.3819,56685,6682,742,317Apr 02 06:07 PM
Leonard Braden Michael10% OwnerApr 02 '25Buy4.0415,20961,4082,757,526Apr 02 06:07 PM
Leonard Braden Michael10% OwnerMar 26 '25Buy5.0420,407102,841125,207Mar 27 07:06 PM
Leonard Braden Michael10% OwnerMar 18 '25Buy4.6962,341292,4182,667,161Mar 20 08:02 PM
Leonard Braden Michael10% OwnerMar 20 '25Buy5.6130,600171,7672,722,761Mar 20 08:02 PM
Leonard Braden Michael10% OwnerMar 19 '25Buy4.9425,000123,3902,692,161Mar 20 08:02 PM
Leonard Braden Michael10% OwnerFeb 26 '25Buy4.01164,886660,9792,432,950Feb 28 04:04 PM
Leonard Braden Michael10% OwnerFeb 28 '25Buy4.6085,068391,0152,604,820Feb 28 04:04 PM
Leonard Braden Michael10% OwnerFeb 27 '25Buy4.4686,802387,0942,519,752Feb 28 04:04 PM
Leonard Braden Michael10% OwnerJul 30 '24Buy7.1585,800613,4702,268,064Jul 31 04:19 PM
Leonard Braden Michael10% OwnerJul 17 '24Buy7.75135,5461,049,9262,101,546Jul 18 09:16 PM
Leonard Braden Michael10% OwnerJul 18 '24Buy9.1180,718735,7362,182,264Jul 18 09:16 PM